Anbio Biotechnology (NASDAQ:NNNN) Trading Down 6.9% – What’s Next?

Anbio Biotechnology (NASDAQ:NNNNGet Free Report) shares traded down 6.9% during mid-day trading on Monday . The company traded as low as $23.01 and last traded at $23.98. 23,722 shares were traded during mid-day trading, a decline of 65% from the average session volume of 67,086 shares. The stock had previously closed at $25.76.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Anbio Biotechnology from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, February 9th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company presently has a consensus rating of “Hold”.

Get Our Latest Research Report on Anbio Biotechnology

Anbio Biotechnology Stock Performance

Anbio Biotechnology (NASDAQ:NNNNGet Free Report) last announced its earnings results on Tuesday, December 30th. The company reported $0.04 earnings per share (EPS) for the quarter. The business had revenue of $2.29 million for the quarter.

Anbio Biotechnology Company Profile

(Get Free Report)

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.

See Also

Receive News & Ratings for Anbio Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anbio Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.